On 14 July 2026 ADM and The EVERY Company announced that OvoPro, EVERY’s precision-fermented ovalbumin, would be made at commercial scale at ADM’s Clinton, Iowa complex. The release said the partnership would leverage “ADM’s cutting-edge precision fermentation production capabilities”. Kris Lutt, ADM’s vice president for Innovation and Growth, described “ADM’s industry-leading precision fermentation capabilities” and said the company would “continue investing in Clinton”.
Thirty-eight days later, the State of Iowa published what that investment is. On 21 August 2026 the Iowa Economic Development Authority board awarded ADM $2.23 million in tax credits against a $55.5 million capital project to “convert an underutilized 463,503-square-foot fermentation facility at its Clinton complex into a precision fermentation facility”.
Both statements are accurate. Read together they answer a question the July release did not: what, physically, is the US base for EVERY’s egg protein today, and what has to be built before it can ship.
What the state record says
The IEDA press release is the primary document, and it is unusually specific for an incentive announcement. Its operative paragraph:
ADM plans to convert an underutilized 463,503-square-foot fermentation facility at its Clinton complex into a precision fermentation facility, expanding the site’s ability to produce additional high-value biobased products. The project includes new processing equipment for separation, purification, drying and packaging, as well as upgrades to existing fermentation equipment, piping and supporting systems to enable large-scale production of proteins and enzymes.
| Item | Figure | Source |
|---|---|---|
| Capital investment | $55.5 million | IEDA, 21 Aug 2026 |
| State tax credits awarded | $2.23 million | IEDA, 21 Aug 2026 |
| Programme | Business Incentives for Growth (BIG) | IEDA, 21 Aug 2026 |
| Floor area to be converted | 463,503 sq ft | IEDA, 21 Aug 2026 |
| Current status of that area | “Underutilized” | IEDA, 21 Aug 2026 |
| Jobs incented | 53 | IEDA, 21 Aug 2026 |
| Qualifying wage | $23.57 per hour | IEDA, 21 Aug 2026 |
| Products named | “Proteins and enzymes”; “additional high-value biobased products” | IEDA, 21 Aug 2026 |
| End markets named | Food, feed, agricultural and industrial applications | vegconomist, 24 Aug 2026 — not in the IEDA text |
The board’s own totals corroborate the figures. IEDA reported 98 jobs and $57.2 million in new capital investment across the two manufacturers approved that day; ADM’s 53 jobs plus Impact CNC’s 45 gives 98, and $55.5 million plus $1.7 million gives $57.2 million. The arithmetic closes.
Two derived figures follow directly. The credit is 4.0% of the stated capital cost, and about $42,000 per incented job. At 2,080 hours the qualifying wage annualises to roughly $49,000.
Practical consequence: state incentive filings are the most reliable published source of capital and floor-area data on fermentation sites in the US, because the numbers are submitted to obtain money and are audited against job and wage commitments. When a supplier will not give you a capex or a footprint, check whether the host state has already published one.
The word that matters is “underutilized”, and the equipment list explains it
A 463,503 sq ft fermentation building is very large. For scale, MicroHarvest’s Leuna plant — described by its own promoters as Europe’s first industrial-scale microbial protein facility, designed for 15,000 tonnes a year — has a gross floor area of about 5,800 m², or roughly 62,400 sq ft. ADM’s underused Clinton space is about 7.4 times that floor area. This is not a company short of steel.
The constraint the $55.5 million addresses is not tank volume. Read the equipment list again: separation, purification, drying and packaging are new; fermentation equipment, piping and supporting systems are upgraded. That is the downstream train, and downstream is where precision fermentation economics are usually decided. A recombinant protein has to be separated from biomass, captured, polished, concentrated and dried to a food-grade powder that meets a specification. Fermenters that were adequate for a commodity output stream are not automatically adequate for an ingredient sold on purity and functionality, and the recovery section is frequently the part that was never built for it.
So “underutilized” is doing precise work. It does not mean empty. It means installed capacity whose current configuration does not produce the products ADM now intends to produce there, and the gap is priced at $55.5 million.
Practical consequence: when a co-manufacturer cites installed fermentation capacity, ask separately about downstream recovery capacity for your specific product — separation, purification, drying, packaging — and about the food-grade qualification status of that train. Litres upstream and kilograms of saleable powder downstream are different assets, and the second one is what you are buying.
The through-line: EVERY has now announced two production bases, and disclosed the volume of neither
This is the second time in three months that EVERY has announced a manufacturing arrangement whose capacity cannot be read off the announcement.
| Announcement | Date | Site | Capacity disclosed |
|---|---|---|---|
| Huvepharma / Biovet expansion | 15 June 2026 | Peshtera area, Bulgaria | A “4x” multiple, with no stated base in the release |
| ADM partnership | 14 July 2026 | Clinton, Iowa, USA | None — no volume, no tonnage, no capex, no date |
| IEDA award (ADM, not EVERY) | 21 August 2026 | Clinton, Iowa, USA | No product volume; $55.5m capex, 463,503 sq ft, 53 jobs |
We examined the Bulgarian announcement in EVERY’s OvoPro: a 4x on 63,000 litres inside a 9-million-litre pharma estate, where the only base figure in the public record — 63,000 litres in 2025, doubled at the start of 2026 — came from a trade interview rather than the wire. The US announcement gives less again: the ADM release contains no quantity of any kind. What we now know about Clinton comes not from either company but from a state incentive filing, and that filing describes the building, not the product.
Note what the IEDA text does and does not say. It names “proteins and enzymes” and “additional high-value biobased products”. It does not name EVERY, OvoPro or ovalbumin. (The wider framing of end markets — “food, feed, agricultural and industrial applications” — comes from vegconomist’s report of the award, not from the IEDA release itself; we have kept the two separate above.) The converted facility is a multi-product asset; EVERY is one tenant of it, as it is one tenant of Biovet’s estate in Bulgaria. Nothing in the public record establishes what share of the Clinton line is contracted to OvoPro.
Practical consequence: if you are underwriting OvoPro as a supply line, the two announced bases are a Bulgarian pharma site in the middle of a reallocation and an Iowa building in the middle of a $55.5 million conversion. Neither is a running food-grade OvoPro line at disclosed volume today. Ask for contracted allocation and a qualification date, in writing, per site.
Why ADM is doing this at Clinton specifically
The industrial logic is sound and worth stating plainly, because it is the strongest argument against reading “underutilized” as a negative signal.
Clinton is a corn processing complex. It makes dextrose. Dextrose is the feedstock for most precision fermentation, and feedstock delivered by pipe from the same site avoids the freight, handling and margin stack that a standalone fermentation plant pays. The site already has fermentation assets, utilities, effluent handling, permits and a workforce. Converting underused space inside an operating complex is materially cheaper and faster than greenfield construction — which is precisely why the number is $55.5 million rather than the sums usually quoted for new build.
That comparison is worth making explicit. EVERY’s own chief executive, Arturo Elizondo, has told Green Queen that wholly owned facilities “are often +$200M and have multi-year lead times”. Against that, $55.5 million to convert 463,503 sq ft of existing, connected, permitted fermentation space is a good trade. The brownfield route is the right route. The point of this piece is not that ADM is doing something questionable; it is that the announcement and the filing describe different stages of the same asset, and only one of them was published by the companies.
The counter-argument
A reasonable objection: incentive filings systematically describe assets in the least flattering terms available, because underuse is what justifies the award. “Underutilized” is a term of art in an application for public money, and a company seeking credits has every reason to present a site as needing them. On this reading, ADM’s July language and Iowa’s August language are both positioning, aimed at different audiences, and the truth is somewhere between.
That is fair, and we accept part of it. But the incentive framing cuts the other way on the capital number. A firm claiming credits must substantiate the spend, and the award is conditioned on job and wage commitments that are audited. The $55.5 million, the 53 jobs and the $23.57 wage are the parts of this record with enforcement behind them. And the equipment list — new separation, purification, drying and packaging — is a description of scope, not an adjective. Whatever weight you give to “underutilized”, the downstream train is being bought now.
What we could not establish
- The start date. Neither ADM’s release nor the IEDA announcement gives a commercial production date for OvoPro at Clinton. Trade coverage has reported the plant is scheduled to begin commercial production of the ingredient “next year”, which would mean 2027; that date appears in secondary reporting and in neither primary document. We have not been able to source it to ADM or EVERY directly.
- OvoPro’s share of the converted facility. Not published. The IEDA description covers proteins and enzymes for food, feed, agricultural and industrial uses; no allocation to any customer is stated.
- Output volume. No tonnage, litreage or capacity figure appears in any of the primary documents for the Clinton site.
- Whether the $55.5 million is dedicated to OvoPro. The filing describes a multi-product conversion. We found no basis to attribute the spend to any single customer, and have not.
- ADM’s earnings-call commentary. Trade coverage attributes remarks on precision fermentation, dextrose and the Bond pet-food project to chairman and CEO Juan Luciano at ADM’s second-quarter 2026 results. We were unable to verify those remarks against a transcript, and have therefore not quoted them.
- The condition of the existing fermentation equipment. “Upgrades to existing fermentation equipment, piping and supporting systems” does not tell us what fraction of the fermenters are being retained, requalified or replaced.
What to watch
Three testable things.
First, whether a capacity figure ever appears for Clinton. EVERY has now announced two manufacturing bases without publishing a volume for either. If the third disclosure — a qualification, a first shipment, a customer supply agreement — again carries a multiple rather than a quantity, that is a disclosure practice rather than a coincidence.
Second, the IEDA compliance record. BIG awards carry job and wage commitments that are reported against. Those filings are public, they are dated, and they will show whether the 53 jobs materialise on schedule. That is a harder timeline signal than any press release.
Third, whether ADM names a second tenant. The filing describes a multi-product facility, and Clinton already hosts fermentation infrastructure built with Spiber for Brewed Protein polymers alongside the EVERY agreement. If ADM announces further precision-fermentation customers at Clinton, the $55.5 million is a platform investment and OvoPro’s share of it falls. That matters directly to anyone relying on the site for supply security, and it is the single variable most likely to move within the next year.